PAX2 and nonpapillary renal cell carcinoma: Gupta et al. conducted a study involving 200 renal tumors and found that almost all ccRCC were immunoreactive for PAX2 (28/30, 93%), whereas more than half (53%) of PRCC expressed PAX2, while most of ChRCC (94%) were non-immunoreactive for PAX2 [15].